R&D News | pharmaphorum

News

West Chester - Circa November 2020: AstraZeneca plant. AstraZeneca has been working on a vaccine for the Coronavirus, COVID and COVID-19.

AstraZeneca goes bigger in amyloidosis with Neurimmune deal

AstraZeneca has clearly made the rare disease transthyretin amyloidosis (ATTR) a key component of its rare disease pipeline, licensing a second drug candidate in the space of a couple of mo

News

Another big AI deal as Sanofi taps Exscientia for 15 new dru...

If the last couple of days is an indication, 2022 is already shaping up to be the year of big-ticket alliances between big pharma companies and specialists in artificial intelligence-driven

News

Amgen pledges $1.9bn to alliance with AI specialist Generate

Fresh from a sizeable funding round that raised $370 million, artificial intelligence-based drug discovery firm Generate Biomedicines has just signed its first major partnering deal with Am

News

Psilocybin is a naturally occurring psychedelic prodrug compound produced by more than 200 species of mushrooms, collectively known as psilocybin mushrooms.

Otsuka dips its toe in psychedelic waters, backing Mindset P...

Despite the growing interest in developing medicines based on psychedelic compounds, big pharma has seemed a bit wary of getting involved, leaving the task to small start-ups.

News

PureTech challenges Roche's Esbriet in head-to-head IPF tria...

Roche's idiopathic pulmonary fibrosis (IPF) therapy Esbriet is already being squeezed by its main rival in the market, and could come under renewed pressure if another competitor from PureT

News